Ranbaxy wants to go ahead with its expansion plans though American regulators blocked imports of company’s 31 medicines over quality issues.
The company is also considering to start selling a recently approved generic version of acne drug Accutane in about six months.
Ranbaxy CEO Arun Sawhney was quoted by The Aossciate Press as saying that "the US, as a total business, will remain the most important to us."
The company is also working to expand generic sales in emerging markets such as India, China, Brazil and Russia.